Relapsed Or Refractory B Cell Malignancies clinical trials

Explore recruiting relapsed or refractory b cell malignancies clinical trials.

Recruiting relapsed or refractory b cell malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory B Cell Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Italy, Germany, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies.

Spain, France, Greece, Romania, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A single-arm, multicenter, open-label, Phase I/II trial of Allo-QuadCAR01-T, an allogeneic CAR-T-cell therapy targeting CD19 and CD20, for the treatment of relapsed or refractory B-cell malignancies

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND FEASIBILITY OF POINT-OF-CARE HUMAN-CD19 TARGETING CAR T-CELLS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (PACMAN)

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T cell-engaging Antibody Targeting CD20 in Subjects with Relapsed or Refractory B-Cell Malignancies (TITANium)

Spain, Germany, Denmark, Italy, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Relapsed Or Refractory B Cell Malignancies trials by city

Relapsed Or Refractory B Cell Malignancies in Toronto Relapsed Or Refractory B Cell Malignancies in Vancouver Relapsed Or Refractory B Cell Malignancies in Montreal Relapsed Or Refractory B Cell Malignancies in Calgary Relapsed Or Refractory B Cell Malignancies in Edmonton Relapsed Or Refractory B Cell Malignancies in Ottawa Relapsed Or Refractory B Cell Malignancies in Winnipeg Relapsed Or Refractory B Cell Malignancies in Quebec City Relapsed Or Refractory B Cell Malignancies in Hamilton Relapsed Or Refractory B Cell Malignancies in Kitchener Relapsed Or Refractory B Cell Malignancies in London Relapsed Or Refractory B Cell Malignancies in Halifax Relapsed Or Refractory B Cell Malignancies in New York Relapsed Or Refractory B Cell Malignancies in Los Angeles Relapsed Or Refractory B Cell Malignancies in Chicago Relapsed Or Refractory B Cell Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease